BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 16, Issue 9
This Article
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (158)
All Articles published online
The chart showing PDF series, HTML series.
Item 
Count 
PDF8
HTML55
 Sum=63
Publishing Process of This Article
The chart showing Browse series, Download series.
Item 
Count 
Browse47
Download33
 Sum=80
Sep 24, 2025 (publication date) through Oct 2, 2025
Times Cited of This Article
  • Times Cited  (0)
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Sep 24, 2025; 16(9): 111537
Published online Sep 24, 2025. doi: 10.5306/wjco.v16.i9.111537
Are we overestimating success of salvage hepatectomy in unresectable hepatocellular carcinoma?
Babu Lal Meena, Deepti Sharma
Babu Lal Meena, Department of Hepatology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India
Deepti Sharma, Department of Radiation Oncology, Institute of Liver and Biliary Sciences, New Delhi 110070, India
Co-first authors: Babu Lal Meena and Deepti Sharma.
Author contributions: Sharma D and Meena BL contributed to concept and design and writing of article and they are co-first authors. All authors approved the manuscript and its submission to the journal.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Deepti Sharma, MD, Associate Professor, Department of Radiation Oncology, Institute of liver and Biliary Sciences, Vasant Kuunj, New Delhi 110070, India. drdeeptisharma16@gmail.com
Received: July 2, 2025
Revised: July 25, 2025
Accepted: August 20, 2025
Published online: September 24, 2025
Processing time: 83 Days and 11.8 Hours
Core Tip

Core Tip: The primary treatment modality for advanced hepatocellular carcinoma is systemic therapy. However, downstaging can be done with use of locoregional modalities like trans arterial chemoembolization, transarterial radioembolization, radiation therapy etc. along with systemic therapies (tyrosine kinase inhibitors and immune checkpoint inhibitor) followed by salvage surgery results in improved survival with limited adverse effects, if patient selection is judiciously made.
Write to the Help Desk
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345